Exploring a new imaging tracer for cancer detection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the biological distribution of a novel tracer, 68Ga-FAPI-JNU, in patients with malignant tumors using PET/CT imaging. After administering the tracer, imaging is performed approximately one hour later, and the distribution is evaluated by experienced diagnostic physicians. The study aims to map standardized uptake values in both primary and metastatic tissues, providing insights into the tracer's effectiveness in cancer detection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The subjects sign the informed consent voluntarily and can complete the test according to the protocol requirements;
2. Age 18-85 years old, male or female;
3. Clinically diagnosed as malignant tumor, diagnostic criteria refer to biopsy or other imaging such as CT and MRI;
4. ECOG score is 0-3 points;

Exclusion Criteria:

1. Patients with a history or allergic constitution to any component of the developer, including alcohol;
2. pregnant or lactating women;
3. Patients with mental illness or related history;
4. Patients who cannot or cannot undergo a PET/CT scan;

Where it's running

• Affiated Hospital of Jiangnan University
  Wuxi, Jiangsu, China Recruiting

Study contacts

• Study coordinator: chunjing Yu
• Email: ycj_wxd1978@163.com
• Phone: 15312238622

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Theranostic PET for target validation and tumor detection in solid cancers

  This is an observational effort to see how theranostic PET scans reflect tumor targets and help with staging, restaging, and treatment planning for adults with solid cancers.

  Recruiting University Hospital, Essen · Essen · NCT07664410

• Cold exposure with PD-1/PD-L1 immunotherapy in solid tumors

  This phase 1 study tests whether adding controlled cold exposure to standard PD-1/PD-L1 therapy is safe and feasible in adults with solid tumors.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07538479

• 177Lu-IM-3050, a targeted radiopharmaceutical for advanced solid tumors.

  This trial will test whether the targeted radioactive drug 177Lu-IM-3050 is safe and can shrink FAP-positive advanced solid tumors in adults who have not responded to standard treatments.

  Recruiting at 5 sites Phase 1 Immunome, Inc. · Dothan, Alabama and 4 other locations · NCT07505771

• CMAB017 for safety and tolerability in advanced solid tumors

  This trial tests whether the experimental antibody CMAB017 is safe and tolerated in adults with advanced solid tumors who have exhausted or declined standard treatments.

  Recruiting Phase 1 Taizhou Mabtech Pharmaceutical Co.,Ltd · Shanghai · NCT06933069

• Testing IM-1021 for advanced cancer treatment

  This study is testing a new treatment called IM-1021 to see if it can safely help people with advanced cancer feel better.

  Recruiting at 24 sites Phase 1 Immunome, Inc. · Duarte, California and 23 other locations · NCT06823167

• SKB571 for adults with advanced solid tumors

  This first-in-human Phase 1 test gives SKB571 to adults with advanced or metastatic solid tumors to see if it is safe, how the body handles it, and whether it shows anti-tumor activity.

  Recruiting at 13 sites Phase 1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Guangzhou, Guangdong and 14 other locations · NCT06725381

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.